芦可替尼-话题@MedSci

#芦可替尼#

3篇内容 | 1156人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2234035, encodeId=d27e223403588, content=<a href='/topic/show?id=8b5086891a9' target=_blank style='color:#2F92EE;'>#芦可替尼#</a> <a href='/topic/show?id=ac1d120e8784' target=_blank style='color:#2F92EE;'>#急性GVHD#</a>, objectTitle=【STTT】芦可替尼联合类固醇治疗急性GVHD的中国3期随机研究结果, objectType=article, longId=849044, objectId=55b684904405, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240801/1722497612738_8538692.jpg, objectUrl=/article/show_article.do?id=55b684904405, replyNumber=0, likeNumber=18, createdTime=2024-10-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=55b684904405, moduleTitle=【STTT】芦可替尼联合类固醇治疗急性GVHD的中国3期随机研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b684904405)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2206520, encodeId=03f02206520ea, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a> <a href='/topic/show?id=b4975869e17' target=_blank style='color:#2F92EE;'>#新辅助化疗#</a> <a href='/topic/show?id=8b5086891a9' target=_blank style='color:#2F92EE;'>#芦可替尼#</a> <a href='/topic/show?id=b4dc114838d0' target=_blank style='color:#2F92EE;'>#Ⅱ期随机对照研究#</a>, objectTitle=JCO | 芦可替尼与一线新辅助化疗联合治疗晚期卵巢癌的I期和II期随机对照研究, objectType=article, longId=827387, objectId=96e282e387b1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240524/1716562435240_6145188.png, objectUrl=/article/show_article.do?id=96e282e387b1, replyNumber=0, likeNumber=113, createdTime=2024-05-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=96e282e387b1, moduleTitle=JCO | 芦可替尼与一线新辅助化疗联合治疗晚期卵巢癌的I期和II期随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96e282e387b1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1941843, encodeId=21ac194184300, content=<a href='/topic/show?id=8b5086891a9' target=_blank style='color:#2F92EE;'>#芦可替尼#</a>, objectTitle=Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究, objectType=article, longId=192565, objectId=2ba3192565fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ba3192565fa, replyNumber=0, likeNumber=79, createdTime=2020-08-30, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ba3192565fa, moduleTitle=Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ba3192565fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941841, encodeId=bc27194184108, content=<a href='/topic/show?id=8b5086891a9' target=_blank style='color:#2F92EE;'>#芦可替尼#</a>, objectTitle=Blood：JAK2抑制剂芦可替尼上市后的思考, objectType=article, longId=138017, objectId=3e8713801eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e8713801eaf, replyNumber=0, likeNumber=102, createdTime=2018-05-31, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e8713801eaf, moduleTitle=Blood：JAK2抑制剂芦可替尼上市后的思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e8713801eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941842, encodeId=7209194184263, content=<a href='/topic/show?id=8b5086891a9' target=_blank style='color:#2F92EE;'>#芦可替尼#</a>, objectTitle=2018 奥地利共识：芦可替尼治疗骨髓纤维化, objectType=article, longId=145478, objectId=cc2d1454e82b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc2d1454e82b, replyNumber=0, likeNumber=0, createdTime=2019-05-18, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc2d1454e82b, moduleTitle=2018 奥地利共识：芦可替尼治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc2d1454e82b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

芦可替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#芦可替尼# #急性GVHD#

【STTT】芦可替尼联合类固醇治疗急性GVHD的中国3期随机研究结果

2024-10-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#卵巢癌# #新辅助化疗# #芦可替尼# #Ⅱ期随机对照研究#

JCO | 芦可替尼与一线新辅助化疗联合治疗晚期卵巢癌的I期和II期随机对照研究

2024-05-25发表于上海

qingting (审核中...)

前往app查看评论内容

#芦可替尼#

Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究

2020-08-30

qingting (审核中...)

前往app查看评论内容

#芦可替尼#

Blood：JAK2抑制剂芦可替尼上市后的思考

2018-05-31

qingting (审核中...)

前往app查看评论内容

#芦可替尼#

2018 奥地利共识：芦可替尼治疗骨髓纤维化

2019-05-18

科室
- - 订阅+
  - 更多科室
工具
服务